<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708821</url>
  </required_header>
  <id_info>
    <org_study_id>The Dex-AC Study</org_study_id>
    <nct_id>NCT04708821</nct_id>
  </id_info>
  <brief_title>DEXTENZA Therapy for Treatment of Allergic Conjunctivitis</brief_title>
  <official_title>DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, open-label, single-center, randomized, investigator-sponsored clinical&#xD;
      study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical&#xD;
      steroid or antihistamine treatment in patients with allergic conjunctivitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at Day 30 (final visit)</measure>
    <time_frame>30 days</time_frame>
    <description>Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at Day 30 (final visit)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bilateral Conjunctivitis (Disorder)</condition>
  <arm_group>
    <arm_group_label>DEXTENZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antihistamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone ophthalmic insert 0.4Mg</intervention_name>
    <description>Dextenza 0.4Mg Ophthalmic Insert</description>
    <arm_group_label>DEXTENZA</arm_group_label>
    <other_name>Dextenza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2% loteprednol etabonate ophthalmic suspension</intervention_name>
    <description>0.2% loteprednol etabonate ophthalmic suspension</description>
    <arm_group_label>Topical Steroid</arm_group_label>
    <other_name>ALREX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olopatadine hydrochloride ophthalmic solution 0.7%</intervention_name>
    <description>olopatadine hydrochloride ophthalmic solution 0.7%</description>
    <arm_group_label>Antihistamine</arm_group_label>
    <other_name>PAZEO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age&#xD;
&#xD;
          -  Provide written informed consent and sign HIPAA form&#xD;
&#xD;
          -  Be willing and able to follow all instructions and attend all study visits&#xD;
&#xD;
          -  Be able and willing to discontinue wearing contact lenses throughout the study period&#xD;
&#xD;
          -  Have a BCVA of ≥50 ETDRS letters (20/100 Snellen equivalent or better) in each eye as&#xD;
             measured at Screening visit&#xD;
&#xD;
          -  Have urine pregnancy testing for women considered capable of becoming pregnant; not be&#xD;
             lactating; and agree to use a medically acceptable form of birth control throughout&#xD;
             the study period&#xD;
&#xD;
          -  Have a positive history of bilateral ocular allergies and a positive skin test&#xD;
             reaction to a perennial allergen and a seasonal allergen as confirmed by the allergy&#xD;
             testing at the Screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Known contraindications or sensitivities to the use of any of the medications&#xD;
             required per protocol, including known steroid responders&#xD;
&#xD;
               -  Have any ocular condition that in the opinion of the Investigator could affect&#xD;
                  the subject's safety or study parameters (including, but not limited to&#xD;
                  uncontrolled narrow angle glaucoma, severe blepharitis, follicular&#xD;
                  conjunctivitis, iritis, pterygium, dry eye diagnosis, or active ocular infection)&#xD;
&#xD;
               -  Have a known history of retinal detachment, diabetic retinopathy, or active&#xD;
                  retinal disease&#xD;
&#xD;
               -  Use of systemic, inhaled, or nasal steroids&#xD;
&#xD;
               -  Use of new systemic antihistamine use within 30 days of Screening visit&#xD;
&#xD;
               -  Use of ocular or topical non-steroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
               -  Use of lid scrubs&#xD;
&#xD;
               -  Use of decongestants&#xD;
&#xD;
               -  Use of immunotherapeutic agents&#xD;
&#xD;
               -  Use of monoamine oxidase inhibitors (MAOIs)&#xD;
&#xD;
               -  Have a congenital or ocular anomaly or anomaly of the punctum that may preclude&#xD;
                  placement of DEXTENZA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jordan Herman</last_name>
    <phone>954-946-8873</phone>
    <email>jordan@floridacrc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jordan Herman</last_name>
      <phone>954-946-8873</phone>
      <email>jordan@floridacrc.com</email>
    </contact>
    <investigator>
      <last_name>Shani Reich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

